Arrhythmias & electrophysiology

Surgical neuromodulation therapies to prevent postoperative atrial fibrillation: A meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials

Heart RhythmPublished meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials

Pooled result · POAFResult — go to the resultRisk ratio 0.62 CI 0.48–0.79

Authors' conclusion

This meta-analysis found a significant reduction in POAF incidence with implementation of AFP preservation, PCD, and PVI. Epicardial injections were effective only for patients undergoing coronary bypass.

Study context

Population
Patients undergoing cardiac surgery in randomized controlled trials of surgical neuromodulation therapiesanterior fat pad (AFP) preservation 7 · pulmonary vein isolation (PVI) 5 · ganglionated plexus ablation 2 · partial cardiac denervation (PCD) 1 · epicardial injections 5
Participants
3,348 patients20 trials
Comparison
Surgical neuromodulation therapies to prevent postoperative atrial fibrillation
Outcome
POAF

Pooled result

As reported in the abstract

Risk ratio

0.62

CI 0.48–0.79

P < 0.001

SNMT
risk ratio 0.62 (CI 0.48–0.79); P < 0.001

Further pooled results

Hospital stay

Surgical neuromodulation therapies (SNMTs) also reduced hospital stay
P = 0.03

Postoperative atrial fibrillation (POAF) with epicardial injections (subgroup)

Epicardial injections were effective only in patients undergoing coronary surgery

Meta-regression

All meta-regression analyses were insignificant

Trial sequential analysis

In the trial sequential analysis, a positive effect for POAF was observed

Original publication

Surgical neuromodulation therapies to prevent postoperative atrial fibrillation: A meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials. Heart Rhythm. Published 4 April 2025. doi:10.1016/j.hrthm.2025.03.2003

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.